Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV
Conditions
Interventions
- BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
Sponsor
Fundación Huésped
Collaborators
- [object Object]
- [object Object]
- [object Object]